RASSF4 and neoplasm: Further studies on combined targeted therapy confirmed that restoring RASSF4 expression using demethylating agents such as 5-Aza-2′-deoxycytidine enhances tumor cell sensitivity to cisplatin, suggesting that the RASSF4 methylation status may serve as a potential biomarker for predicting responses to epigenetic therapy [28,45,48].